Evotec launches J.TRAIN biologics manufacturing
Analysis based on 9 articles · First reported Jun 30, 2026 · Last updated Jun 30, 2026
The launch of J.TRAIN by Evotec SE is expected to positively impact the biotechnology and pharmaceutical sectors by offering a faster, more cost-effective, and flexible solution for biologics manufacturing. This innovation could lead to increased productivity and reduced operating costs for companies adopting the technology, potentially boosting Evotec's market share and revenue.
Evotec SE, through its wholly-owned subsidiary Evotec — Just – Evotec Biologics, has launched J.TRAIN, a new turnkey service offering that allows biopharmaceutical companies to deploy Evotec's proprietary continuous manufacturing technology directly within their own facilities. This platform combines prefabricated modular cleanrooms, industry-standard equipment, and cGMP-compliant process automation to enable significantly faster and more cost-effective deployment compared to traditional manufacturing expansion. J.TRAIN aims to increase capacity and manufacture biologics at reduced costs and improved productivity, with deployment possible in as little as 18 months. The model was validated by a December 2025 transaction with Novartis — Sandoz, which included a manufacturing facility and a license to Evotec's technology. The solution was unveiled in April 2026 at the INTERPHEX conference in New York City.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard